Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Role of JMJD6 in Breast Tumourigenesis.

Poulard C, Rambaud J, Lavergne E, Jacquemetton J, Renoir JM, Trédan O, Chabaud S, Treilleux I, Corbo L, Le Romancer M.

PLoS One. 2015 May 7;10(5):e0126181. doi: 10.1371/journal.pone.0126181. eCollection 2015.

2.

Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.

Gaudichon J, Milano F, Cahu J, DaCosta L, Martens AC, Renoir JM, Sola B.

PLoS One. 2014 Sep 25;9(9):e107009. doi: 10.1371/journal.pone.0107009. eCollection 2014.

3.

Synthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors.

Audisio D, Methy-Gonnot D, Radanyi C, Renoir JM, Denis S, Sauvage F, Vergnaud-Gauduchon J, Brion JD, Messaoudi S, Alami M.

Eur J Med Chem. 2014 Aug 18;83:498-507. doi: 10.1016/j.ejmech.2014.06.067. Epub 2014 Jun 28.

PMID:
24992077
4.

Suppressor of cytokine signaling 1 modulates invasion and metastatic potential of colorectal cancer cells.

David M, Naudin C, Letourneur M, Polrot M, Renoir JM, Lazar V, Dessen P, Roche S, Bertoglio J, Pierre J.

Mol Oncol. 2014 Jul;8(5):942-55. doi: 10.1016/j.molonc.2014.03.014. Epub 2014 Mar 25.

5.

Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism.

Sola B, Poirot M, de Medina P, Bustany S, Marsaud V, Silvente-Poirot S, Renoir JM.

Oncotarget. 2013 Jun;4(6):911-22.

6.

4-Hydroxy-tamoxifen-loaded liposomes have potent anti-myeloma activity.

Urbinati G, Marsaud V, Renoir JM, Sola B.

Leuk Lymphoma. 2013 Aug;54(8):1808-10. doi: 10.3109/10428194.2012.757764. Epub 2013 Jan 8. No abstract available.

PMID:
23228023
7.

Estrogen receptor signaling as a target for novel breast cancer therapeutics.

Renoir JM, Marsaud V, Lazennec G.

Biochem Pharmacol. 2013 Feb 15;85(4):449-65. doi: 10.1016/j.bcp.2012.10.018. Epub 2012 Oct 24. Review.

8.

Anticancer drugs in liposomal nanodevices: a target delivery for a targeted therapy.

Urbinati G, Marsaud V, Renoir JM.

Curr Top Med Chem. 2012;12(15):1693-712. Review.

PMID:
22978336
9.

Estradiol receptors in breast cancer cells: associated co-factors as targets for new therapeutic approaches.

Renoir JM.

Steroids. 2012 Oct;77(12):1249-61. doi: 10.1016/j.steroids.2012.07.019. Epub 2012 Aug 11. Review.

PMID:
22917634
10.

Cracking the estrogen receptor's posttranslational code in breast tumors.

Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L.

Endocr Rev. 2011 Oct;32(5):597-622. doi: 10.1210/er.2010-0016. Epub 2011 Jun 15. Review.

PMID:
21680538
11.

Liposomal trichostatin A: therapeutic potential in hormone-dependent and -independent breast cancer xenograft models.

Urbinati G, Marsaud V, Nicolas V, Vergnaud-Gauduchon J, Renoir JM.

Horm Mol Biol Clin Investig. 2011 May 1;6(2):215-25. doi: 10.1515/HMBCI.2011.005.

PMID:
25961258
12.

Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery.

Audisio D, Messaoudi S, Cegielkowski L, Peyrat JF, Brion JD, Methy-Gonnot D, Radanyi C, Renoir JM, Alami M.

ChemMedChem. 2011 May 2;6(5):804-15. doi: 10.1002/cmdc.201000489. Epub 2011 Mar 4.

PMID:
21374821
13.

Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy.

Urbinati G, Marsaud V, Plassat V, Fattal E, Lesieur S, Renoir JM.

Int J Pharm. 2010 Sep 15;397(1-2):184-93. doi: 10.1016/j.ijpharm.2010.06.046. Epub 2010 Jul 23.

PMID:
20603204
14.

Cyclin K and cyclin D1b are oncogenic in myeloma cells.

Marsaud V, Tchakarska G, Andrieux G, Liu JM, Dembele D, Jost B, Wdzieczak-Bakala J, Renoir JM, Sola B.

Mol Cancer. 2010 May 10;9:103. doi: 10.1186/1476-4598-9-103.

15.

Therapeutic potential of new 4-hydroxy-tamoxifen-loaded pH-gradient liposomes in a multiple myeloma experimental model.

Urbinati G, Audisio D, Marsaud V, Plassat V, Arpicco S, Sola B, Fattal E, Renoir JM.

Pharm Res. 2010 Feb;27(2):327-39. doi: 10.1007/s11095-009-0023-z. Epub 2009 Dec 23.

PMID:
20033476
16.

Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells.

Rouf MA, Vural I, Renoir JM, Hincal AA.

J Liposome Res. 2009;19(4):322-31. doi: 10.3109/08982100902963043.

PMID:
19863167
17.

Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor alpha and anti-oestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts.

Bouclier C, Marsaud V, Bawa O, Nicolas V, Moine L, Opolon P, Renoir JM.

Breast Cancer Res Treat. 2010 Jul;122(1):145-58. doi: 10.1007/s10549-009-0558-z. Epub 2009 Sep 22.

PMID:
19771505
18.

Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.

Reddy LH, Renoir JM, Marsaud V, Lepetre-Mouelhi S, Desmaële D, Couvreur P.

Mol Pharm. 2009 Sep-Oct;6(5):1526-35. doi: 10.1021/mp900099e.

PMID:
19634915
19.

Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells.

Surace C, Arpicco S, Dufaÿ-Wojcicki A, Marsaud V, Bouclier C, Clay D, Cattel L, Renoir JM, Fattal E.

Mol Pharm. 2009 Jul-Aug;6(4):1062-73. doi: 10.1021/mp800215d.

PMID:
19413341
20.

Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells.

Taetz S, Bochot A, Surace C, Arpicco S, Renoir JM, Schaefer UF, Marsaud V, Kerdine-Roemer S, Lehr CM, Fattal E.

Oligonucleotides. 2009 Jun;19(2):103-16. doi: 10.1089/oli.2008.0168.

PMID:
19374532
21.

Tosylcyclonovobiocic acids promote cleavage of the hsp90-associated cochaperone p23.

Radanyi C, Le Bras G, Bouclier C, Messaoudi S, Peyrat JF, Brion JD, Alami M, Renoir JM.

Biochem Biophys Res Commun. 2009 Feb 6;379(2):514-8. doi: 10.1016/j.bbrc.2008.12.102. Epub 2008 Dec 30.

PMID:
19118525
22.

Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells.

Radanyi C, Le Bras G, Marsaud V, Peyrat JF, Messaoudi S, Catelli MG, Brion JD, Alami M, Renoir JM.

Cancer Lett. 2009 Feb 8;274(1):88-94. doi: 10.1016/j.canlet.2008.09.001. Epub 2008 Oct 7.

PMID:
18842335
23.

Physicochemical characteristics and preliminary in vivo biological evaluation of nanocapsules loaded with siRNA targeting estrogen receptor alpha.

Bouclier C, Moine L, Hillaireau H, Marsaud V, Connault E, Opolon P, Couvreur P, Fattal E, Renoir JM.

Biomacromolecules. 2008 Oct;9(10):2881-90. doi: 10.1021/bm800664c. Epub 2008 Sep 13.

PMID:
18788777
24.

Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells.

Renoir JM, Bouclier C, Seguin A, Marsaud V, Sola B.

J Mol Endocrinol. 2008 Mar;40(3):101-12. doi: 10.1677/JME-07-0143. Review.

PMID:
18316469
25.

Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90).

Radanyi C, Le Bras G, Messaoudi S, Bouclier C, Peyrat JF, Brion JD, Marsaud V, Renoir JM, Alami M.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2495-8. doi: 10.1016/j.bmcl.2008.01.128. Epub 2008 Feb 14.

PMID:
18304811
26.
27.

New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.

Le Bras G, Radanyi C, Peyrat JF, Brion JD, Alami M, Marsaud V, Stella B, Renoir JM.

J Med Chem. 2007 Nov 29;50(24):6189-200. Epub 2007 Nov 3.

PMID:
17979263
28.

Estrogenic or antiestrogenic therapies for multiple myeloma?

Sola B, Renoir JM.

Mol Cancer. 2007 Sep 24;6:59. Review.

29.

Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules.

Stella B, Arpicco S, Rocco F, Marsaud V, Renoir JM, Cattel L, Couvreur P.

Int J Pharm. 2007 Nov 1;344(1-2):71-7. Epub 2007 Jun 14.

PMID:
17651931
30.

Nanoparticles loaded with ferrocenyl tamoxifen derivatives for breast cancer treatment.

Nguyen A, Marsaud V, Bouclier C, Top S, Vessieres A, Pigeon P, Gref R, Legrand P, Jaouen G, Renoir JM.

Int J Pharm. 2008 Jan 22;347(1-2):128-35. Epub 2007 Jun 26.

PMID:
17643877
31.

Alternative cyclin D1 forms a and b have different biological functions in the cell cycle of B lymphocytes.

Lévêque C, Marsaud V, Renoir JM, Sola B.

Exp Cell Res. 2007 Jul 15;313(12):2719-29. Epub 2007 Apr 24.

PMID:
17499716
32.
33.

Biological characterization of folic acid-conjugated poly(H2NPEGCA-co-HDCA) nanoparticles in cellular models.

Stella B, Marsaud V, Arpicco S, Géraud G, Cattel L, Couvreur P, Renoir JM.

J Drug Target. 2007 Feb;15(2):146-53.

PMID:
17365286
34.

International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors.

Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA.

Pharmacol Rev. 2006 Dec;58(4):782-97. Review. No abstract available.

PMID:
17132855
35.

Squalenoyl nanomedicines as potential therapeutics.

Couvreur P, Stella B, Reddy LH, Hillaireau H, Dubernet C, Desmaële D, Lepêtre-Mouelhi S, Rocco F, Dereuddre-Bosquet N, Clayette P, Rosilio V, Marsaud V, Renoir JM, Cattel L.

Nano Lett. 2006 Nov;6(11):2544-8.

PMID:
17090088
36.

Improved anti-tumoral capacity of mixed and pure anti-oestrogens in breast cancer cell xenografts after their administration by entrapment in colloidal nanosystems.

Renoir JM, Stella B, Ameller T, Connault E, Opolon P, Marsaud V.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):114-27. Epub 2006 Oct 23. Review.

PMID:
17056251
37.

Antiestrogenic therapies in solid cancers and multiple myeloma.

Sola B, Renoir JM.

Curr Mol Med. 2006 Jun;6(4):359-68. Review.

PMID:
16900659
38.

Improved antitumoral properties of pure antiestrogen RU 58668-loaded liposomes in multiple myeloma.

Maillard S, Gauduchon J, Marsaud V, Gouilleux F, Connault E, Opolon P, Fattal E, Sola B, Renoir JM.

J Steroid Biochem Mol Biol. 2006 Jul;100(1-3):67-78. Epub 2006 Jun 5.

PMID:
16753295
39.

Tamoxifen citrate loaded amphiphilic beta-cyclodextrin nanoparticles: in vitro characterization and cytotoxicity.

Memisoglu-Bilensoy E, Vural I, Bochot A, Renoir JM, Duchene D, Hincal AA.

J Control Release. 2005 Jun 2;104(3):489-96. Epub 2005 Apr 25.

PMID:
15911048
40.

Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma.

Maillard S, Ameller T, Gauduchon J, Gougelet A, Gouilleux F, Legrand P, Marsaud V, Fattal E, Sola B, Renoir JM.

J Steroid Biochem Mol Biol. 2005 Feb;94(1-3):111-21. Epub 2005 Jan 27.

PMID:
15862956
41.

Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.

Gougelet A, Bouclier C, Marsaud V, Maillard S, Mueller SO, Korach KS, Renoir JM.

J Steroid Biochem Mol Biol. 2005 Feb;94(1-3):71-81. Epub 2005 Feb 23.

PMID:
15862952
42.
43.

Drug delivery systems for oestrogenic hormones and antagonists: the need for selective targeting in estradiol-dependent cancers.

Ameller T, Legrand P, Marsaud V, Renoir JM.

J Steroid Biochem Mol Biol. 2004 Sep;92(1-2):1-18. Review.

PMID:
15544926
44.

Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines.

Atallah D, Marsaud V, Radanyi C, Kornprobst M, Rouzier R, Elias D, Renoir JM.

Int J Hyperthermia. 2004 Jun;20(4):405-19.

PMID:
15204521
45.

Pure antiestrogen RU 58668-loaded nanospheres: morphology, cell activity and toxicity studies.

Ameller T, Marsaud V, Legrand P, Gref R, Renoir JM.

Eur J Pharm Sci. 2004 Feb;21(2-3):361-70.

PMID:
14757510
46.

p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.

Carroll JS, Lynch DK, Swarbrick A, Renoir JM, Sarcevic B, Daly RJ, Musgrove EA, Sutherland RL.

Cancer Res. 2003 Aug 1;63(15):4322-6.

47.

Potent competitive inhibition of drug binding to the Saccharomyces cerevisiae ABC exporter Pdr5p by the hydrophobic estradiol-derivative RU49953.

Conseil G, Perez-Victoria JM, Renoir JM, Goffeau A, Di Pietro A.

Biochim Biophys Acta. 2003 Aug 7;1614(2):131-4.

48.

Polyester-poly(ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 58668: physicochemical and opsonization properties.

Ameller T, Marsaud V, Legrand P, Gref R, Barratt G, Renoir JM.

Pharm Res. 2003 Jul;20(7):1063-70.

PMID:
12880293
50.

Supplemental Content

Loading ...
Support Center